Skip to main content
NCBI home page
Protein Science : A Publication of the Protein Society logoLink to Protein Science : A Publication of the Protein Society
. 1996 Nov;5(11):2226–2235. doi: 10.1002/pro.5560051109

Serpin alpha 1proteinase inhibitor probed by intrinsic tryptophan fluorescence spectroscopy.

H Koloczek 1, A Banbula 1, G S Salvesen 1, J Potempa 1
PMCID: PMC2143291  PMID: 8931141

Abstract

Various conformational forms of the archetypal serpin human alpha 1proteinase inhibitor (alpha 1PI), including ordered polymers, active and inactive monomers, and heterogeneous aggregates, have been produced by refolding from mild denaturing conditions. These forms presumably originate by different folding pathways during renaturation, under the influence of the A and C sheets of the molecule. Because alpha 1PI contains only two Trp residues, at positions 194 and 238, it is amenable to fluorescence quenching resolved spectra and red-edge excitation measurements of the Trp environment. Thus, it is possible to define the conformation of the various forms based on the observed fluorescent properties of each of the Trp residues measured under a range of conditions. We show that denaturation in GuHCl, or thermal denaturation in Tris, followed by renaturation, leads to the formation of polymers that contain solvent-exposed Trp 238, which we interpret as ordered head-to-tail polymers (A-sheet polymers). However, thermal denaturation in citrate leads to shorter polymers where some of the Trp 238 residues are not solvent accessible, which we interpret as polymers capped by head-to-head interactions via the C sheet. The latter treatment also generates monomers thought to represent a latent form, but in which the environment of Trp 238 is occluded by ionized groups. These data indicate that the folding pathway of alpha 1PI, and presumably other serpins, is sensitive to solvent composition that affects the affinity of the reactive site loop for the A sheet or the C sheet.

Full Text

The Full Text of this article is available as a PDF (3.7 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aulak K. S., Eldering E., Hack C. E., Lubbers Y. P., Harrison R. A., Mast A., Cicardi M., Davis A. E., 3rd A hinge region mutation in C1-inhibitor (Ala436-->Thr) results in nonsubstrate-like behavior and in polymerization of the molecule. J Biol Chem. 1993 Aug 25;268(24):18088–18094. [PubMed] [Google Scholar]
  2. Baumann U., Bode W., Huber R., Travis J., Potempa J. Crystal structure of cleaved equine leucocyte elastase inhibitor determined at 1.95 A resolution. J Mol Biol. 1992 Aug 20;226(4):1207–1218. doi: 10.1016/0022-2836(92)91062-t. [DOI] [PubMed] [Google Scholar]
  3. Baumann U., Huber R., Bode W., Grosse D., Lesjak M., Laurell C. B. Crystal structure of cleaved human alpha 1-antichymotrypsin at 2.7 A resolution and its comparison with other serpins. J Mol Biol. 1991 Apr 5;218(3):595–606. doi: 10.1016/0022-2836(91)90704-a. [DOI] [PubMed] [Google Scholar]
  4. Björk I., Nordling K., Larsson I., Olson S. T. Kinetic characterization of the substrate reaction between a complex of antithrombin with a synthetic reactive-bond loop tetradecapeptide and four target proteinases of the inhibitor. J Biol Chem. 1992 Sep 25;267(27):19047–19050. [PubMed] [Google Scholar]
  5. Björk I., Nordling K., Olson S. T. Immunologic evidence for insertion of the reactive-bond loop of antithrombin into the A beta-sheet of the inhibitor during trapping of target proteinases. Biochemistry. 1993 Jul 6;32(26):6501–6505. doi: 10.1021/bi00077a002. [DOI] [PubMed] [Google Scholar]
  6. Bruce D., Perry D. J., Borg J. Y., Carrell R. W., Wardell M. R. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn-->Asp) J Clin Invest. 1994 Dec;94(6):2265–2274. doi: 10.1172/JCI117589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bruch M., Bieth J. G. Influence of elastin on the inhibition of leucocyte elastase by alpha 1-proteinase inhibitor and bronchial inhibitor. Potent inhibition of elastin-bound elastase by bronchial inhibitor. Biochem J. 1986 Aug 15;238(1):269–273. doi: 10.1042/bj2380269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Carrell R. W., Stein P. E., Fermi G., Wardell M. R. Biological implications of a 3 A structure of dimeric antithrombin. Structure. 1994 Apr 15;2(4):257–270. doi: 10.1016/s0969-2126(00)00028-9. [DOI] [PubMed] [Google Scholar]
  9. Demchenko A. P. Red-edge-excitation fluorescence spectroscopy of single-tryptophan proteins. Eur Biophys J. 1988;16(2):121–129. doi: 10.1007/BF00255522. [DOI] [PubMed] [Google Scholar]
  10. Eldering E., Verpy E., Roem D., Meo T., Tosi M. COOH-terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion and subsequent multimerization. J Biol Chem. 1995 Feb 10;270(6):2579–2587. doi: 10.1074/jbc.270.6.2579. [DOI] [PubMed] [Google Scholar]
  11. Hekman C. M., Loskutoff D. J. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem. 1985 Sep 25;260(21):11581–11587. [PubMed] [Google Scholar]
  12. Hopkins P. C., Carrell R. W., Stone S. R. Effects of mutations in the hinge region of serpins. Biochemistry. 1993 Aug 3;32(30):7650–7657. doi: 10.1021/bi00081a008. [DOI] [PubMed] [Google Scholar]
  13. Katz D. S., Christianson D. W. Modeling the uncleaved serpin antichymotrypsin and its chymotrypsin complex. Protein Eng. 1993 Sep;6(7):701–709. doi: 10.1093/protein/6.7.701. [DOI] [PubMed] [Google Scholar]
  14. Kim J., Lee K. N., Yi G. S., Yu M. H. A thermostable mutation located at the hydrophobic core of alpha 1-antitrypsin suppresses the folding defect of the Z-type variant. J Biol Chem. 1995 Apr 14;270(15):8597–8601. doi: 10.1074/jbc.270.15.8597. [DOI] [PubMed] [Google Scholar]
  15. Kołoczek H., Waśniowska A., Potempa J., Wasylewski Z. The fluorescence quenching resolved spectra and red-edge excitation fluorescence measurements of human alpha 1-proteinase inhibitor. Biochim Biophys Acta. 1991 Apr 9;1073(3):619–625. doi: 10.1016/0304-4165(91)90239-d. [DOI] [PubMed] [Google Scholar]
  16. Lawrence D. A., Olson S. T., Palaniappan S., Ginsburg D. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition. J Biol Chem. 1994 Nov 4;269(44):27657–27662. [PubMed] [Google Scholar]
  17. Lomas D. A., Evans D. L., Finch J. T., Carrell R. W. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992 Jun 18;357(6379):605–607. doi: 10.1038/357605a0. [DOI] [PubMed] [Google Scholar]
  18. Lomas D. A., Evans D. L., Stone S. R., Chang W. S., Carrell R. W. Effect of the Z mutation on the physical and inhibitory properties of alpha 1-antitrypsin. Biochemistry. 1993 Jan 19;32(2):500–508. doi: 10.1021/bi00053a014. [DOI] [PubMed] [Google Scholar]
  19. Mast A. E., Enghild J. J., Salvesen G. Conformation of the reactive site loop of alpha 1-proteinase inhibitor probed by limited proteolysis. Biochemistry. 1992 Mar 17;31(10):2720–2728. doi: 10.1021/bi00125a012. [DOI] [PubMed] [Google Scholar]
  20. Mikus P., Ny T. Intracellular polymerization of the serpin plasminogen activator inhibitor type 2. J Biol Chem. 1996 Apr 26;271(17):10048–10053. doi: 10.1074/jbc.271.17.10048. [DOI] [PubMed] [Google Scholar]
  21. Mikus P., Urano T., Liljeström P., Ny T. Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms. Eur J Biochem. 1993 Dec 15;218(3):1071–1082. doi: 10.1111/j.1432-1033.1993.tb18467.x. [DOI] [PubMed] [Google Scholar]
  22. Schreuder H. A., de Boer B., Dijkema R., Mulders J., Theunissen H. J., Grootenhuis P. D., Hol W. G. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nat Struct Biol. 1994 Jan;1(1):48–54. doi: 10.1038/nsb0194-48. [DOI] [PubMed] [Google Scholar]
  23. Schulze A. J., Frohnert P. W., Engh R. A., Huber R. Evidence for the extent of insertion of the active site loop of intact alpha 1 proteinase inhibitor in beta-sheet A. Biochemistry. 1992 Aug 25;31(33):7560–7565. doi: 10.1021/bi00148a017. [DOI] [PubMed] [Google Scholar]
  24. Song H. K., Lee K. N., Kwon K. S., Yu M. H., Suh S. W. Crystal structure of an uncleaved alpha 1-antitrypsin reveals the conformation of its inhibitory reactive loop. FEBS Lett. 1995 Dec 18;377(2):150–154. doi: 10.1016/0014-5793(95)01331-8. [DOI] [PubMed] [Google Scholar]
  25. Stein P. E., Leslie A. G., Finch J. T., Turnell W. G., McLaughlin P. J., Carrell R. W. Crystal structure of ovalbumin as a model for the reactive centre of serpins. Nature. 1990 Sep 6;347(6288):99–102. doi: 10.1038/347099a0. [DOI] [PubMed] [Google Scholar]
  26. Wasylewski Z., poloczek H., Wasniowska A. Fluorescence-quenching-resolved spectroscopy of proteins. Eur J Biochem. 1988 Mar 15;172(3):719–724. doi: 10.1111/j.1432-1033.1988.tb13948.x. [DOI] [PubMed] [Google Scholar]
  27. Wright H. T., Qian H. X., Huber R. Crystal structure of plakalbumin, a proteolytically nicked form of ovalbumin. Its relationship to the structure of cleaved alpha-1-proteinase inhibitor. J Mol Biol. 1990 Jun 5;213(3):513–528. doi: 10.1016/s0022-2836(05)80212-8. [DOI] [PubMed] [Google Scholar]
  28. Wright H. T., Scarsdale J. N. Structural basis for serpin inhibitor activity. Proteins. 1995 Jul;22(3):210–225. doi: 10.1002/prot.340220303. [DOI] [PubMed] [Google Scholar]

Articles from Protein Science : A Publication of the Protein Society are provided here courtesy of The Protein Society

RESOURCES